Author

K. Rezvani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

K. Chen· 4 shared D. Marin· 3 shared E. Gokdemir· 3 shared H. Shaim· 3 shared J. Dou· 3 shared L. Muniz-Feliciano· 3 shared M. Daher· 3 shared M. Mendt· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

K. Chen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

COP9 Signalosome Promotes Neointimal Hyperplasia via Deneddylation and CSN5-Mediated Nuclear Export

S. Giri, C. Suo, R. Pardi, G. A. Fishbein, K. Rezvani, Y. Chen, X. Wang

This study shows that the COP9 signalosome promotes neointimal hyperplasia via deneddylation and CSN5-mediated nuclear export of p27 in vascular smooth muscle cells.

bioRxiv · Apr 11, 2023Cell Biology

ANTIBODY-INDEPENDENT ANTITUMOR EFFECTS OF CD32A-CHIMERIC RECEPTOR T CELLS: IMPLICATIONS FOR BREAST CANCER PROGNOSIS AND TREATMENT.

G. Sconocchia, G. Lanzilli, V. Cesarini, D. A. Sivestris, R. Arriga, K. Rezvani, S. Caratelli, K. Chen, J. Dou, C. Cenciarelli, G. Toietta, S. Baldari, T. Sconocchia, F. De Paolis, A. Aureli, , G. C. Spagnoli

This study shows CD32A-chimeric receptor T cells can identify CD32A ligands, predict breast cancer sensitivity, and improve prognosis without antibodies.

bioRxiv · Dec 22, 2021 · PreprintImmunology

Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy

R. Basar, N. Uprety, E. Ensley, M. Daher, K. Klein, F. Martinez, F. Aung, M. Shanley, B. Hu, E. Gokdemir, M. Mendt, F. Reyes Silva, S. Acharya, T. Laskowski, L. Muniz-Feliciano, , K. Rezvani

The paper expands SARS-CoV-2 T-cells from COVID-19 donors using IL-2/4/7 cytokines, achieving >1000-fold expansion with preserved function, and inactivates the glucocorticoid receptor to create glucocorticoid-resistant T-cells for adoptive therapy.

bioRxiv · Sep 15, 2020Immunology

Inhibition of the av integrin-TGF-b axis improves natural killer cell function against glioblastoma stem cells

H. Shaim, M. Hernandez Sanabria, R. Basar, F. Wang, M. Daher, D. Zamler, J. Gumin, K. Gabrusiewicz, Q. Miao, J. Dou, A. Alsuliman, L. Kerbauy, S. Acharya, V. Mohanty, P. Banerjee, , K. Rezvani

The paper shows that inhibiting the integrin-TGF-β axis enhances NK cell function against glioblastoma stem cells, suggesting it as a therapeutic target.

bioRxiv · Mar 30, 2020 · PreprintImmunology

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

K. Rezvani, M. Daher, R. Basar, E. Gokdemir, N. Baran, N. Uprety, M. Mendt, L. Kerbauy, M. Hernandez Sanabria, N. Imahashi, A. Nunez, L. Li, M. Fathi, A. Rezvan, V. Mohanty, , Wei Inn

This paper combines CIS checkpoint deletion with CAR engineering in NK cells to enhance their metabolic fitness and anti-tumor activity in a lymphoma model.

bioRxiv · Mar 29, 2020 · PreprintImmunology